← Back to Home

Letting Cells Assemble Bacterial Vaccines: AstraZeneca Acquires Partner Omniose

Moving from an exclusive research collaboration to an acquisition, AstraZeneca is bringing a bioconjugation platform in-house to address challenges in bacterial vaccine manufacturing. Whether the technology can deliver more consistent, effective products still depends on clearing the hurdles of manufacturing scale-up and human trials.

By SURL BioNews

In bacterial vaccine development, the challenge sometimes lies in how molecules are assembled: how can bacterial polysaccharide antigens be attached to carrier proteins to produce vaccines of consistent quality? AstraZeneca has chosen to bring in-house a technology that could simplify this process. U.S. biotech company Omniose announced on November 10 that it had been acquired and had become a wholly owned subsidiary of AstraZeneca’s infectious diseases unit. Financial terms were not disclosed.

The acquisition builds on nearly three years of research collaboration. According to Fierce Biotech and Reuters, the companies began an exclusive collaboration in early 2024 to explore vaccines targeting bacterial pathogens, including multidrug-resistant bacteria. Omniose’s bioconjugation platform and research and development expertise are now formally part of AstraZeneca, supporting its preclinical vaccine programs.

The basic approach to conjugate vaccines is to link bacterial polysaccharide antigens to carrier proteins. Traditional manufacturing relies on chemical conjugation, involving complex processing and quality control. Omniose seeks to put cells in charge of assembly: a single engineered Escherichia coli cell produces the polysaccharide antigen, the carrier protein, and the enzyme responsible for linking the two, allowing both component production and conjugation to take place inside the cell.

According to Omniose’s description of its technology, this enzyme-driven approach could enable more precise molecular design and simplify the steps involved in traditional chemical conjugation. The company also claims that its platform can handle a broader range of bacterial polysaccharides. These potential advantages, however, require individual validation; completing conjugation inside a cell does not directly imply lower manufacturing costs at scale or better protection after vaccination.

BioPharm International noted that the announcement did not disclose the target pathogens or development timelines for the programs involved in the acquisition, nor did it provide data on clinical safety, immune responses, manufacturing yields, or costs. Fierce Biotech reported that Omniose had previously used the platform in Klebsiella pneumoniae research and reported sustained immune responses in mice. These early findings still cannot substitute for evidence of protective efficacy in humans, nor can they establish which development areas will take priority following the acquisition.

The shift from collaboration to full ownership means AstraZeneca is integrating this manufacturing technology more deeply into its vaccine research and development strategy. The key questions now are which vaccine candidates will advance first and whether intracellular assembly can maintain consistent quality as manufacturing scales up. The deal gives the platform access to a major pharmaceutical company’s development resources, but manufacturing and clinical hurdles remain before it can yield vaccines available for administration.

References

  1. Fierce Biotech
  2. Reuters via Euronext
  3. BioPharm International